Dimethyl fumarate - Almirall

Drug Profile

Dimethyl fumarate - Almirall

Alternative Names: LAS-41008; Skilarence

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Almirall S.A.
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Preregistration Plaque psoriasis

Most Recent Events

  • 21 Apr 2017 Committee for Medicinal Products for Human Use (CHMP) of the EMA recommends approval of Dimethyl fumarate for Plaque psoriasis in European Union
  • 01 Nov 2016 Almirall completes a phase I pharmacokinetics trial in United Kingdom (PO) (NCT02955693)
  • 28 Sep 2016 Efficacy data from the BRIDGE (phase III) trial in Plaque psoriasis released by Almirall
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top